M
Michael J. Birrer
Researcher at University of Arkansas for Medical Sciences
Publications - 579
Citations - 64433
Michael J. Birrer is an academic researcher from University of Arkansas for Medical Sciences. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 102, co-authored 554 publications receiving 54218 citations. Previous affiliations of Michael J. Birrer include University of Texas MD Anderson Cancer Center & University of Arkansas at Little Rock.
Papers
More filters
Journal ArticleDOI
An in situ cell to study phase transitions in individual aerosol particles on a substrate using scanning transmission x-ray microspectroscopy.
Thomas Huthwelker,Veronika Zelenay,Michael J. Birrer,Adela Krepelova,Jörg Raabe,George Tzvetkov,Martine G.C. Vernooij,Markus Ammann +7 more
TL;DR: The function of the cell is demonstrated using two systems of submicron size: inorganic sodium bromide aerosols and soot originating from a diesel passenger car, and it is demonstrated that the uptake of water onto individual soot particles can be studied.
Journal ArticleDOI
Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis.
Kyunghee Noh,Kyunghee Noh,Lingegowda S. Mangala,Hee Dong Han,Ningyan Zhang,Sunila Pradeep,Sunila Pradeep,Sherry Y. Wu,Shaolin Ma,Edna M. Mora,Edna M. Mora,Rajesha Rupaimoole,Dahai Jiang,Yunfei Wen,Mian M.K. Shahzad,Yasmin A. Lyons,Min Soon Cho,Wei Hu,Archana S. Nagaraja,Monika Haemmerle,Celia S.L. Mak,Xiuhui Chen,Kshipra M. Gharpure,Hui Deng,Wei Xiong,Charles V. Kingsley,Jinsong Liu,Nicholas B. Jennings,Michael J. Birrer,Richard R. Bouchard,Gabriel Lopez-Berestein,Robert L. Coleman,Zhiqiang An,Anil K. Sood +33 more
TL;DR: In contrast to its antagonistic effects on tumor angiogenesis, EGFL6 blockage did not affect normal wound healing, and these findings have significant implications for development of anti-angiogenesis therapies.
Journal ArticleDOI
Anticancer immunotherapy by MFAP5 blockade inhibits fibrosis and enhances chemosensitivity in ovarian and pancreatic cancer
Tsz-Lun Yeung,Cecilia S. Leung,Kay-Pong Yip,Jianting Sheng,Long Vien,Laura C. Bover,Laura C. Bover,Michael J. Birrer,Stephen T. C. Wong,Stephen T. C. Wong,Samuel C. Mok,Samuel C. Mok +11 more
TL;DR: Evaluated data suggest that MFAP5 blockade using an immunologic approach inhibits fibrosis, induces tumor vessel normalization, and enhances chemosensitivity in ovarian and pancreatic cancer, and can be used as a novel therapeutic agent.
Journal ArticleDOI
The human L-myc gene encodes multiple nuclear phosphoproteins from alternatively processed mRNAs.
J De Greve,James F. Battey,J Fedorko,Michael J. Birrer,G Evan,Frederic J. Kaye,Edward A. Sausville,John D. Minna +7 more
TL;DR: Two phosphorylated L-myc proteins with molecular masses of 60,000 and 66,000 daltons are identified in a small-cell carcinoma line expressing high levels of L- myc mRNA, suggesting that alternative RNA processing of the L-Myc transcript could play a role in determining the steady-state levels of the p60L-myC and p66L- myC proteins.
Journal ArticleDOI
Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: A NRG oncology/Gynecologic Oncology Group (GOG) study.
Robert A. Burger,Danielle Enserro,Krishnansu S. Tewari,Mark F. Brady,Michael A. Bookman,Gini F. Fleming,Helen Q. Huang,Howard D. Homesley,Jeffrey M. Fowler,Matthew P. Boente,Leslie M. Randall,John K. Chan,James Stuart Ferris,Philip J. DiSaia,Larry J. Copeland,Robert S. Mannel,Michael J. Birrer,Bradley J. Monk +17 more
TL;DR: GOG 0218 is a double-blind, placebo-controlled, phase 3 randomized trial studying chemotherapy with and without concurrent BEV, and with concurrent BeV followed by maintenance BEV f...